Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 May 5;219(11):1799-1803.
doi: 10.1093/infdis/jiy743.

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

Nicolas Folschweiller  1 , Ulrich Behre, Marc Dionne  2 , Paolo Durando  3   4 , Susanna Esposito  5 , Linda Ferguson  6 , Murdo Ferguson  6 , Peter Hillemanns  7 , Shelly A McNeil  8 , Klaus Peters, Brian Ramjattan  9 , Tino F Schwarz  10 , Khuanchai Supparatpinyo  11 , Pemmaraju V Suryakirian  12 , Michel Janssens  1 , Philippe Moris  1 , Annabelle Decreux  1 , Sylviane Poncelet  1 , Frank Struyf  1
Affiliations
Clinical Trial

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

Nicolas Folschweiller et al. J Infect Dis. .

Abstract

This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following 3 doses in women aged 15-25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970.

Keywords: AS04-HPV-16/18 vaccine; HPV-31; HPV-45; cross-reactivity; immunogenicity; nonvaccine types.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Human papillomavirus type 31 (HPV-31; A) and HPV-45 (B) geometric mean concentrations (GMCs) by enzyme-linked immunosorbent assay at each time point for initially seronegative subjects in the month 36 (for the HPV-070 study) or month 60 (for the HPV-048 study) according-to-protocol cohort for immunogenicity. CI, confidence interval; 2D, 2-dose schedule of the AS04-adjuvanted HPV-16/18 vaccine; 3D, 3-dose schedule of the AS04-adjuvanted HPV-16/18 vaccine. aThe GMC at month 0 was equal to half of the assay cutoff (29.5 ELISA units/mL).
Figure 2.
Figure 2.
Human papillomavirus type 31 (HPV-31)–specific (A) and HPV-45–specific (B) CD4+ T-cell responses and HPV 31–specific (C) and HPV-45–specific (D) memory B-cell responses for initially seronegative subjects from the HPV-070 study who were in the month 36 according-to-protocol cohort for immunogenicity. Upper and lower limits of boxes denote interquartile ranges, horizontal lines inside boxes and bars denote median values, and whiskers denote maximum and minimum values. 2D, 2-dose schedule of the AS04-adjuvanted HPV-16/18 vaccine; 3D, 3-dose schedule of the AS04-adjuvanted HPV-16/18 vaccine.
See this image and copyright information in PMC

References

    1. Romanowski B, Schwarz TF, Ferguson L, et al. . Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother 2016; 12:20–9. - PMC - PubMed
    1. Huang LM, Puthanakit T, Cheng-Hsun C, et al. . Sustained immunogenicity of 2-dose human papillomavirus 16/18 AS04-adjuvanted vaccine schedules in girls aged 9-14 years: a randomized trial. J Infect Dis 2017; 215:1711–9. - PMC - PubMed
    1. Lehtinen M, Paavonen J, Wheeler CM, et al. ; HPV PATRICIA Study Group Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89–99. - PubMed
    1. de Sanjose S, Quint WG, Alemany L, et al. ; Retrospective International Survey and HPV Time Trends Study Group Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048–56. - PubMed
    1. World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec 2017; 19: 241–68. - PubMed

Publication types

Associated data